TriangleNCT04798586 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurs first, or censoring date (maximum of 65.1 weeks of treatment)
What was measured
Progression free survival (PFS) was the time from the first date of the study intervention to the date of the first documentation of confirmed progression, or death due to any cause.
Analysis population: SAS included all enrolled participants who received at least 1 dose of study intervention.
Groups in this outcome
Elranatamab
Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
| Group | Source count |
|---|---|
| Elranatamab | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Elranatamab | NA | Not reported | NA | NA | Data for PFS was not planned to be summarized per Statistical Analysis Plan (SAP). Individual data was collected but not reported as it would lead to re-identification of participants. |
Complete source fields
- classes
- categories
- measurements
- comment
- Data for PFS was not planned to be summarized per Statistical Analysis Plan (SAP). Individual data was collected but not reported as it would lead to re-identification of participants.
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 4
- units
- Participants
- description
- Progression free survival (PFS) was the time from the first date of the study intervention to the date of the first documentation of confirmed progression, or death due to any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).
- id
- OG000
- title
- Elranatamab
- param Type
- MEDIAN
- population Description
- SAS included all enrolled participants who received at least 1 dose of study intervention.
- reporting Status
- POSTED
- time Frame
- From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurs first, or censoring date (maximum of 65.1 weeks of treatment)
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice